Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation
Authors:
- 2 April 2007
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 39 (11) , 705-709
Abstract
Immunosuppressive monoclonal antibodies directed to immune system cells may reduce rejection and graft versus host disease (GvHD) after allogeneic stem cell transplantation (SCT), but can increase the risks of viral infection. Here, we report human herpes virus-6 (HHV-6) encephalitis despite antiviral prophylaxis in 5 of 43 (11.6%) patients receiving alemtuzumab supported conditioning. Encephalitis occurred at 41–103 days (median 60 days) presenting with confusion in all patients, combined with amnesia (n=3) or seizures (n=2). MRI revealed non-specific white matter changes in two and a non-enhancing medial temporal lobe lesion in three patients. Cerebrospinal fluid (CSF) PCR amplification for HHV-6 was positive in all five patients, (600–2 25 000 (median 4700) copies/ml CSF), while analysis of peripheral blood revealed 100–22 500 (median 1200) viral copies/ml plasma. CSF protein was elevated in four patients, with minimal CSF pleocytosis. Intravenous foscarnet produced neurological improvement at 8–13 (median 11) days and negative plasma PCR at 30–66 (median 50) days. Four patients had complete neurological recovery, but one patient with persistent viral DNA in the CSF succumbed to progressive encephalopathy. Given this high incidence of HHV-6 and the possibility of successful outcome with prompt treatment, a high index of suspicion of this disorder is required in recipients of monoclonal antibody supported allografts.Keywords
This publication has 21 references indexed in Scilit:
- Risk Factors for Developing Human Herpesvirus 6 (HHV-6) Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation and Its Association with Central Nervous System DisordersTransplantation and Cellular Therapy, 2007
- The Impact of Human Herpesvirus 6B Reactivation on Early Complications following Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2006
- Human Herpesvirus 6 DNA in Plasma after Allogeneic Stem Cell Transplantation: Incidence and Clinical SignificanceThe Journal of Infectious Diseases, 2006
- Quantitative Detection and Differentiation of Human Herpesvirus 6 Subtypes in Bone Marrow Transplant Patients by Using a Single Real-Time Polymerase Chain Reaction AssayTransplantation and Cellular Therapy, 2005
- Clinical Outcomes of Human Herpesvirus 6 Reactivation after Hematopoietic Stem Cell TransplantationClinical Infectious Diseases, 2005
- A Population-Based Study of Primary Human Herpesvirus 6 InfectionNew England Journal of Medicine, 2005
- Human Herpesvirus 6 Viremia in Bone Marrow Transplant Recipients: Clinical Features and Risk FactorsThe Journal of Infectious Diseases, 2002
- Effect of Antivirals on Human Herpesvirus 6 Replication in Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2002
- Fatal Encephalitis Due to Variant B Human Herpesvirus-6 Infection in a Bone Marrow-Transplant RecipientNew England Journal of Medicine, 1994
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974